2^nd International Conference on Tumor & Cancer Immunology and Immunotherapy July 17-18, 2017 Chicago, Illinois, USA

Andrew Wilber has expertise in hematology and immunology. His laboratory is interested in understanding the role of the tumor microenvironment in suppressing anti-tumor immunity. Current efforts are examining deficiencies in natural anti-tumor immunity in patients with advanced kidney cancer. Specifically, his group is studying alterations in natural killer cells within the blood and tumor of these patients. These changes prevent natural killer cells from destroying kidney tumor cells. Prevention of these processes may be an important goal of future tumor therapy.

Tumor, Tumor Immunology

Young Kwang Chae is currently an Assistant Professor of Medicine, Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine & Co-Director of Developmental Therapeutics Program of the Division of Hematology Oncology. He is also an Co-Chair of Multi-Histology Disease Team Meeting, Robert H. Lurie Comprehensive Cancer Center. He won Many Awards such as Samsung Scholarship: tuition and living expense support for the Johns Hopkins University MPH program, October 2004 Johns Hopkins Bloomberg School of Public Health Student Conference Award, April 2006 First place, Clinical Research Award, Albert Einstein Medical Center, May 2009; for outstanding poster presented on the Research Recognition Day and many more

personalized cancer therapy, precision medicine, novel combination cancer therapy, targeted therapy, immunotherapy, biomarker studies, novel drug development, novel drug delivery systems, adaptive clinical trials design, cell signaling pathways, and immune checkpoint pathways.

Masoud H. Manjili is an Associate Professor in the department of Microbiology & Immunology in the VCU School of medicine, Massey Cancer center, USA. He obtained his PhD from Sydney University in 1996. He was also an affiliated member in Roswell Park Cancer Institute (2003-2004). He is an associate Editor of Journal Frontiers in Tumor immunology. Also an Editorial Board Member of Journal of Molecular & Genetic Medicine. He also serves as an Manaing editor of American Association of Immunologists; American Association for Cancer Research; Society for Immunotherapy of Cancer; Society for Thermal Medicine; American Association for the Advancement of Science; International Society of Translational Medicine.

Immunotherapy and cancer dormancy; Tumor Immunology; Tumor Immunoediting; Tumor Recurrence and Metastasis

In 2001, Dr. Han obtained his Ph.D degree in clinical hematology from Chinese PLA Postgraduate Medical School, and worked in Dept. of Molecule & Immunology of Chinese PLA General Hospital. In 2003, he did postdoctoral work at the University College London. In 2006, he was promoted to professor of molecular and cellular biology. Now, he is the Director of Dept. of Molecular and Cellular Biology, Director of Clinical Translational Ward, the General Hospital of PLA. Since 2001, he focused on mechanism research involved in cancer-treatment resistance and clinical translation of cell therapy. He has published over 80 articles.

Cancer- Treatment resistance, Clinical translation of cell therapy

Dr William Cho is a Biomedical Scientist in Queen Elizabeth Hospital. He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), Guest Professor of a number of Universities and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Dr Cho has published over 200 peer-reviewed papers. He serves as the editor-in-chief, editor and associate editor of a number of international medical journals. Dr Cho is also an international renowned grant reviewer of the Hope Funds for Cancer Research (USA), Cancer Research (UK), MRC Research Grant (UK), Health Research Board (Ireland), Science Foundation (Ireland), Istituto Toscano Tumori (Firenze), The Foundation Fournier-Majoie for Innovation (Brussels), National Medical Research Council (Singapore), The Medical Research Council (South Africa), and Academia Sinica Investigator Award (Taiwan), etc.

cancer, cancer diagnosis, treatment prediction and prognostication

Dr. Roza Nurieva is currently an Assistant Professor, Department of Immunology, Tenure-Track, The University of Texas MD Anderson Cancer Center, Houston, TX USA. She is also an Instructor, Department of Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. she is honoured with an The Journal of Biological Chemistry/Herbert Tabor Young Investigator Award, International Cytokine and Interferon Society in 2015 & also published many articles in reputed journals.

Cancer, Immunology, Autoimmunity.

Dr Manal Mohamed Saber, has earned her PhD from Nottingham, UK. she is focusing on cancer studies, EMAP II, immune suppression, molecular, cellular and laboratory techniques at a high level. She received excellent training in molecular and cellular techniques at the highest international level and has previously worked with cancer and immunology studies. Her dedication to cure cancer got her involved in cancer studies

Cancer, Immunology, Cellular Immunology, Molecular Immunology